Bull Harbor Capital LLC Invests $741,000 in Becton, Dickinson and Company $BDX

Bull Harbor Capital LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,714 shares of the medical instruments supplier’s stock, valued at approximately $741,000.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Becton, Dickinson and Company by 4.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after purchasing an additional 26,671 shares during the period. Cooke & Bieler LP grew its holdings in shares of Becton, Dickinson and Company by 27.2% in the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after purchasing an additional 240,673 shares during the last quarter. KLP Kapitalforvaltning AS increased its stake in Becton, Dickinson and Company by 61.2% in the 4th quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock worth $33,493,000 after buying an additional 65,500 shares during the period. Finally, Inlet Private Wealth LLC lifted its holdings in Becton, Dickinson and Company by 1,515.7% during the 4th quarter. Inlet Private Wealth LLC now owns 22,620 shares of the medical instruments supplier’s stock valued at $4,390,000 after buying an additional 21,220 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. UBS Group began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They set a “buy” rating and a $190.00 target price on the stock. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Finally, Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $180.93.

Becton, Dickinson and Company Price Performance

BDX opened at $165.59 on Friday. The firm has a market capitalization of $45.63 billion, a PE ratio of 41.92, a price-to-earnings-growth ratio of 12.00 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The business’s 50-day moving average is $151.48 and its two-hundred day moving average is $163.63. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same period last year, the business earned $3.35 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock valued at $765,661 in the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.